Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FTC-146 PET/MRI for Chronic Pain
NCT06599151Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Oct 2024
- Primary completion
- Oct 2030
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of [18F]-FTC-146 in chronic pain, neuropathic pain and schwannomatosis (2 arms), sponsored by Stanford University. Primary endpoints: Biodistribution of [18F]FTC-146 at 4 hours and Differentiation of Painful vs Non-Painful Schwannomas. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
[18F]-FTC-146
03
Conditions
chronic painneuropathic painschwannomatosis
Beyond the preview
Go deeper on NCT06599151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599151.